Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Quipazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.76 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.76 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.76 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.76 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.76 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.76 |
| ▸ | HTR3B | O95264 | 4/20 | 0.76 |
| ▸ | HTR3A | P46098 | 4/20 | 0.76 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.76 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | HTR7 | P34969 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quipazine SCHEMBL10529419 | 1.00 | KDM4E (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| Quipazine SCHEMBL29868311 | 1.00 | KDM4E (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| Quipazine SCHEMBL322181 | 0.87 | KDM4E (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| Quipazine SCHEMBL4062074 | 0.85 | KDM4E (0.97) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| Maleic Acid SCHEMBL29868216 | 0.84 | KDM4E (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| SCHEMBL3227424 | 0.81 | KDM4E (0.88) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| 6-Nitroquipazine SCHEMBL4266387 | 0.78 | ALDH1A1 (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| 6-Nitroquipazine SCHEMBL4266383 | 0.78 | ALDH1A1 (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| 6-Nitroquipazine SCHEMBL4266389 | 0.78 | ALDH1A1 (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E | |
| SCHEMBL6918242 | 0.78 | KDM4E (0.81) | KDM4ECYP3A4HSD17B10ALDH1A1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20080033029-A1 | Treating Digestive Tract Conditions | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-02-07 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005107473-A2 | TREATING DIGESTIVE TRACT CONDITIONS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2005-11-17 | — | — | WO | claimed |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250367223-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997039355-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | PHARMAPRINT, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5521183-A | Use of 5-HT ligands as anti-pruritic agents | ALLERGAN (US) | 1996-05-28 | — | — | US | disclosed |
| WO-1996006601-A1 | USE OF 5-HT LIGANDS AS ANTI-PRURITIC AGENTS | ALLERGAN (US) | 1996-03-07 | — | — | WO | disclosed |
| US-4880632-A | DZ RECEPTORS DOPAMINE ANTAGONIST, BENZAMIDES | THE UNITED STATES OF AMERICA (US) | 1989-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | ADRB1 318/4885SLC6A4 20/4885HTR1A 11/4885 |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | HTR1D, HTR1B, HTR2B | ADRB1 474/4885SLC6A4 79/4885HTR1A 6/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | ADRB1 2529/4885SLC6A4 120/4885HTR1A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.